Learning objectives:
Describe the current diagnostic, management, and treatment recommendations outlined in the KDIGO Guidelines
Highlight the unmet need with current guideline-recommended treatments
Educate on the burden of disease for IgA nephropathy, the patient journey, and the importance of lowering proteinuria
Educate on the current treatment landscape for IgA nephropathy and how it is evolving with the introduction of newly approved and pipeline treatments
IgA nephropathy is the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and kidney failure. There is an unmet need in the therapeutic landscape for safe, efficacious drugs for patients at high risk of disease progression.
A significant number of patients remain above guideline-recommended proteinuria targets despite optimized supportive care. This webinar will give an overview of current management strategies for IgA nephropathy, showcasing recently approved and pipeline therapeutics to offer a deeper awareness of the evolving treatment landscape.
A recording of this webinar will be available open-access on the ISN Academy.
*This is an industry webinar with content provided by sponsor and not the ISN.
Register now
Access the recording of the webinar on the ISN Academy
What’s New in the Management and Treatment of Glomerulonephritis:
A look at IgAN and MN
Watch the recording
